Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Mar;27(2):125-131.
doi: 10.1089/cap.2016.0107. Epub 2016 Nov 28.

Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder

Lawrence Scahill  1   2 , Karen Bearss  1   2 , Rena Sarhangian  3 , Christopher J McDougle  4   5 , L Eugene Arnold  6 , Michael G Aman  6 , James T McCracken  7 , Elaine Tierney  8 , Scott Gillespie  1   2 , Valentina Postorino  1   2 , Benedetto Vitiello  9
Affiliations
Randomized Controlled Trial

Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder

Lawrence Scahill et al. J Child Adolesc Psychopharmacol. 2017 Mar.

Abstract

Objectives: Parent rating scales are commonly used to evaluate change in clinical trials. Despite advantages, these measures may not capture parental impression of the child's most salient problems. We examine the use of parent target problems (PTPs) in a randomized trial of methylphenidate (MPH) in children with autism spectrum disorder and symptoms of attention-deficit/hyperactivity disorder.

Methods: This multisite, 4-week, randomized crossover trial compared three dose levels (low, medium, and high) of MPH with placebo. At baseline, the independent evaluator (IE) asked parents to nominate the child's two biggest problems. For each problem, the IE and parent coconstructed a brief narrative of the behavior and the impact on family life. The IE and parents reviewed and revised the narratives at subsequent visits. A panel of four judges, blind to treatment condition, independently reviewed the narratives to rate change from baseline on a 9-point scale: 1, normal; 2, markedly improved; 3, definitely improved; 4, equivocally improved; 5, no change; 6, possibly worse; 7, definitely worse; 8, markedly worse; 9, disastrously worse. The mean of the four raters was compared with primary and key secondary ratings from the original study.

Results: Two PTPs were recorded at baseline for 60 participants. The inter-rater reliability of the four judges across all PTPs and time points was excellent (intraclass correlation = 0.95). On the primary outcome measure (Aberrant Behavior Checklist Hyperactivity subscale), the medium and high-dose levels were superior to placebo. On the mean PTP rating, only the high dose was superior to placebo. We also compared PTP cutoff scores 3.0 (definitely improved), 3.25, and 3.5 with the rate of positive response on the Improvement item of the Clinical Global Impressions scale in the original study. Sensitivities ranged from 68% to 88%.

Conclusions: The parent target problem method offers a systematic way to identify and track patient-centered outcomes.

Keywords: autism spectrum disorder; double-blind method; methylphenidate; patient-centered outcomes.

PubMed Disclaimer

References

    1. Aman MG, Singh NN, Stewart AW, Field CJ: The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485–491, 1985 - PubMed
    1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington DC: American Psychiatric Association; 2000
    1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington DC: American Psychiatric Association; 2013
    1. Arnold LE, Vitiello B, McDougle C, Scahill L, Shah B, Gonzalez NM, Chuang S, Davies M, Hollway J, Aman MG, Cronin P, Koenig K, Kohn AE, McMachon DJ, Tierney E: Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials. J Am Acad Child Adolescent Psychiatry 42:1443–1450, 2003 - PubMed
    1. Bearss K, Johnson C, Smith T, Lecavalier L, Swiezy N, Aman M, McAdam DB, Butter E, Stillitano C, Minshawi N, Sukhodolsky D, Mruzek DW, Turner K, Neal T, Hallett V, Mulick JA, Green B, Handen B, Deng Y, Dziura J, Scahill L: Effect of parent training versus parent education on behavioral problems in children with autism spectrum disorder: a randomized clinical trial. JAMA 313:1524–1533, 2015 - PMC - PubMed

Publication types

MeSH terms

Substances